New drug combo shows promise in stomach cancer trial

NCT ID NCT06846346

Recruiting now Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Dec 10, 2025 · Last updated May 16, 2026 · Updated 19 times

Summary

This study tests whether adding the drug ivonescimab to standard chemotherapy can shrink tumors better than chemo alone in people with advanced stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is to see how many patients have their tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Léon Bérard
RECRUITING

Lyon, 69008, France

Contact
Institut Jean Godinot
RECRUITING

Reims, 51100, France

Contact
Institut Paoli Calmettes
NOT_YET_RECRUITING

Marseille, France

Contact
Institut de Cancerologie de l'Ouest - Site René Gauducheau
NOT_YET_RECRUITING

Saint-Herblain, France

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED ESOPHAGEAL ADENOCARCINOMA ADVANCED GASTRIC ADENOCARCINOMA METASTATIC ESOPHAGEAL ADENOCARCINOMA METASTATIC GASTRIC ADENOCARCINOMA